Akero Therapeutics, Inc. (AKRO)
Market Cap | 2.55B |
Revenue (ttm) | n/a |
Net Income (ttm) | -115.52M |
Shares Out | 55.60M |
EPS (ttm) | -2.49 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 37,913 |
Open | 45.37 |
Previous Close | 45.92 |
Day's Range | 45.01 - 45.90 |
52-Week Range | 25.97 - 58.38 |
Beta | -0.93 |
Analysts | Strong Buy |
Price Target | 63.38 (+38.2%) |
Earnings Date | Nov 3, 2023 |
About AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatmen... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $63.38, which is an increase of 38.20% from the latest price.
News

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-- Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, repor...

Weight-loss drugs in development aim to replace injections with pills
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in ...

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses Data show changes in non-invasive tests ...

3 Mid Caps You Haven't Heard Of But Need To Know About
There have been plenty of headlines in recent weeks regarding the influence a few tech titans are having on the broader market rally that's underway, with some voices suggesting the S&P 500 would actu...

Akero says NASH drug shown to reduce liver fat by 65% in some patients
Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic st...

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data

Akero Therapeutics to Present at the Jefferies Healthcare Conference
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease mar...

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter ...

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
The planned Phase 3 program consists of three trials, SYNCHRONY Histology , SYNCHRONY Real-World , and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NAS...

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero's Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks Designat...

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liv...

Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo...

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...

Akero Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab...